[An experimental substantiation for using the "Semax" neuroprotector in the treatment of optic-nerve diseases].
In order to substantiate the feasibility of using the "Semax" neuroprotector in the treatment of optic-nerve diseases its pharmacokinetics in the intranasal administration was studied in experiments with rats; besides, the physical-and-chemical properties of "Semax" were investigated to define the preparation's stability and mobility in the electric field. A series of experiments, involving a tritium-marked "Semax", showed that the peptide actively penetrates into the brain and eyes of experimental animals after its intranasal administration. It was established, within a study aimed at determining the electrophoretic activity and stability of "Semax" in the electric field, that the preparation does not disintegrate in the electric field, it posses the electrophoretic mobility and moves, in the electric field, from plus to minus; therefore, the "Semax" solution must be fed from anode while making the electrophoresis procedure.
Sheremet
N L
NL
Polunin
G S
GS
Ovchinnikov
A N
AN
Kamenskiĭ
A A
AA
Levitskaia
N G
NG
Andreeva
L A
LA
Alfeeva
L Iu
LIu
Nagaev
I Iu
IIu
D000281:Administration, Intranasal; D000324:Adrenocorticotropic Hormone / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics; D000818:Animals; D002540:Cerebral Cortex / Q000378:metabolism; D002853:Chromatography, Liquid; D004195:Disease Models, Animal; D004586:Electrophoresis; D005123:Eye / Q000378:metabolism; D008297:Male; D018696:Neuroprotective Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D009901:Optic Nerve Diseases / Q000188:drug therapy* / Q000378:metabolism; D010446:Peptide Fragments / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D051381:Rats
D018696:Neuroprotective Agents; D010446:Peptide Fragments; C048487:ACTH (4-7), Pro-Gly-Pro-; D000324:Adrenocorticotropic Hormone